Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System

Rhea-AI Summary

Xtant Medical Holdings, Inc. (NYSE American:XTNT) has launched the Cortera Posterior Fixation System, a comprehensive solution for thoracolumbar fixation surgeries. Now available in the United States, Cortera aims to enhance surgical efficiency and provide versatile solutions for complex spine procedures. Key features include:

• Dual Lead and Dual-to-Quad Lead screw thread options
• 5.5/6.0mm Ti/CoCr Rod System
• Helical Flange design
• Universal S27 Hexalobe Drive

The system is designed to simplify both straightforward and complex posterior fixation procedures, addressing spinal deformities, fractures, and degenerative conditions. Xtant Medical will showcase Cortera at the NASS 2024 Annual Meeting in Chicago, IL, from September 25-28, 2024.

Positive

• Launch of Cortera Posterior Fixation System expands Xtant Medical's product portfolio
• Cortera system designed to enhance surgical efficiency and versatility
• Second major product introduction this month, demonstrating commitment to portfolio expansion
• Positive customer feedback and encouraging interest in Cortera system

Negative

• None.

Insights

Medical Device Analyst

The launch of Xtant Medical's Cortera Posterior Fixation System represents a significant expansion of the company's product portfolio. This system addresses a critical need in complex spine procedures, offering enhanced surgical efficiency and versatility. Key features like dual lead screw options, titanium and cobalt-chromium rod compatibility and a universal drive system position Cortera as a comprehensive solution for thoracolumbar fixation. The timing of this launch, coinciding with another major product introduction this month, demonstrates Xtant's aggressive growth strategy in the spinal medical device market. The positive customer feedback and high interest levels suggest potential for increased market share and revenue growth. However, the impact on Xtant's financial performance will depend on adoption rates and the system's ability to differentiate itself in a competitive landscape.

Financial Analyst

This product launch is strategically significant for Xtant Medical, potentially driving revenue growth and market expansion. As the second major product introduction this month, it signals accelerated innovation and portfolio diversification. The Cortera system targets the lucrative spinal surgery market, which could boost Xtant's market position and financial performance. However, investors should note that the full financial impact may take time to materialize as adoption ramps up. Key metrics to watch include sales growth, market share gains and profit margins. The positive customer feedback is encouraging, but it's important to monitor long-term clinical outcomes and competitive positioning. With a market cap of $76.4 million, Xtant is a small-cap player, making this launch particularly important for its growth trajectory. The stock may see increased volatility as the market assesses the product's potential.

New System Enhances Surgical Efficiency and Provides Versatile Solutions for Complex Spine Procedures

BELGRADE, MT / ACCESSWIRE / September 23, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leading global medical technology company focused on the treatment of spinal disorders, is excited to announce the launch of the Cortera Posterior Fixation System, a comprehensive solution designed to streamline thoracolumbar fixation surgeries. Now available to surgeons across the United States through Xtant's commercial channels., Cortera enhances surgical workflows while delivering value across a wide spectrum of complex spinal procedures.

"The Cortera Posterior Fixation System is a significant addition to our growing fixation portfolio," said Sean Browne, President and CEO of Xtant Medical. "With innovative implants and multi-functional instruments, Cortera offers a safe, efficient solution for addressing complex spinal pathologies. This system simplifies procedures while maintaining consistent performance, allowing surgeons to focus on achieving optimal outcomes."

The launch of Cortera marks Xtant's second major product introduction this month, highlighting the company's commitment to expanding its portfolio with cutting-edge technologies. "By introducing new, innovative products, we are expanding our market opportunities," Browne added. "Customer feedback from our new products has been overwhelmingly positive, and the level of interest in Cortera has been very encouraging."

Key Features of the Cortera Posterior Fixation System:
- Simplifies both straightforward and complex posterior fixation procedures
- Dual Lead and Dual-to-Quad Lead screw thread options for greater versatility
- 5.5/6.0mm Ti/CoCr Rod System to enhance strength and stability
- Helical Flange design for secure fixation
- Universal S27 Hexalobe Drive for ease of use

The Cortera system addresses a broad range of patient needs, offering surgeons a reliable and
efficient tool for managing spinal deformities, fractures, and degenerative conditions. By improving workflow and minimizing operative challenges, the system enables more predictable surgical outcomes.

Xtant Medical will showcase the Cortera Posterior Fixation System at the NASS 2024 Annual Meeting, taking place from September 25-28, 2024, at McCormick Place in Chicago, IL. Attendees are invited to visit Booth #4402 to learn more about Cortera and Xtant Medical's Elevated Procedural Solutions.

For additional information about Cortera Posterior Fixation System, please visit https://xtantmedical.com/products/fixation/ or contact sales support at cs@xtantmedical.com or (888) 886-9354.

About Xtant Medical Holdings, Inc.

Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," ‘‘expects,'' ‘‘anticipates,'' ‘‘plans,'' ‘‘believes,'' ‘‘estimates,'' "continue," "future," ‘‘will,'' "potential," "going forward," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's expectations regarding the private placement, the timing for closing and the anticipated gross proceeds and use of net proceeds from the private placement. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: risks and uncertainties surrounding the private placement; the Company's future operating results and financial performance; its ability to increase or maintain revenue; the Company's ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with its acquisitions and the integration of those businesses; the Company's ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory; the ability to remain competitive; the ability to innovate, develop and introduce new products and the success of those products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company's dependence on key independent agents for a significant portion of its revenue; the effect of labor and hospital staffing shortages on the Company's business, operating results and financial condition, especially when they affect key markets; the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company's financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; risks associated with the Company's clinical trials; international risks; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on April 1, 2024 and subsequent SEC filings by the Company. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Investor Relations Contact

Brett Maas
Managing Partner, Hayden IR
brett@haydenir.com
(646) 536-7331

SOURCE: Xtant Medical Holdings

View the original press release on accesswire.com

FAQ

What is the Cortera Posterior Fixation System launched by Xtant Medical (XTNT)?

The Cortera Posterior Fixation System is a comprehensive solution for thoracolumbar fixation surgeries, designed to streamline procedures and provide versatile solutions for complex spine procedures. It features Dual Lead screw options, a 5.5/6.0mm Rod System, and a Helical Flange design for secure fixation.

When and where will Xtant Medical (XTNT) showcase the Cortera system?

Xtant Medical will showcase the Cortera Posterior Fixation System at the NASS 2024 Annual Meeting, taking place from September 25-28, 2024, at McCormick Place in Chicago, IL. Attendees can visit Booth #4402 to learn more about the system.

What spinal conditions can the Cortera system from Xtant Medical (XTNT) address?

The Cortera Posterior Fixation System is designed to address a broad range of patient needs, including spinal deformities, fractures, and degenerative conditions. It offers surgeons a reliable and efficient tool for managing these complex spinal pathologies.

How does the Cortera system impact surgical procedures for Xtant Medical (XTNT)?

The Cortera system simplifies both straightforward and complex posterior fixation procedures, enhancing surgical workflows and minimizing operative challenges. This allows for more predictable surgical outcomes and enables surgeons to focus on achieving optimal results.